These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 22959816)

  • 1. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
    Bergen PJ; Landersdorfer CB; Zhang J; Zhao M; Lee HJ; Nation RL; Li J
    Diagn Microbiol Infect Dis; 2012 Nov; 74(3):213-23. PubMed ID: 22959816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
    Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
    Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.
    Kassamali Z; Jain R; Danziger LH
    Int J Infect Dis; 2015 Jan; 30():125-32. PubMed ID: 25461655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colistin: an update on the antibiotic of the 21st century.
    Biswas S; Brunel JM; Dubus JC; Reynaud-Gaubert M; Rolain JM
    Expert Rev Anti Infect Ther; 2012 Aug; 10(8):917-34. PubMed ID: 23030331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.
    Velkov T; Roberts KD; Nation RL; Thompson PE; Li J
    Future Microbiol; 2013 Jun; 8(6):711-24. PubMed ID: 23701329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymyxins for CNS infections: Pharmacology and neurotoxicity.
    Velkov T; Dai C; Ciccotosto GD; Cappai R; Hoyer D; Li J
    Pharmacol Ther; 2018 Jan; 181():85-90. PubMed ID: 28750947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.
    Falagas ME; Kasiakou SK; Tsiodras S; Michalopoulos A
    Clin Med Res; 2006 Jun; 4(2):138-46. PubMed ID: 16809407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
    Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
    Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyxin B versus colistin: an update.
    Cai Y; Lee W; Kwa AL
    Expert Rev Anti Infect Ther; 2015; 13(12):1481-97. PubMed ID: 26488563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational use of intravenous polymyxin B and colistin: A review.
    Zakuan ZD; Suresh K
    Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance.
    Cheah SE; Li J; Tsuji BT; Forrest A; Bulitta JB; Nation RL
    Antimicrob Agents Chemother; 2016 Jul; 60(7):3921-33. PubMed ID: 27067324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.
    Lin YW; Zhou Q; Onufrak NJ; Wirth V; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
    Kassamali Z; Danziger L
    Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rescuing the Last-Line Polymyxins: Achievements and Challenges.
    Nang SC; Azad MAK; Velkov T; Zhou QT; Li J
    Pharmacol Rev; 2021 Apr; 73(2):679-728. PubMed ID: 33627412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.
    Bergen PJ; Bulman ZP; Saju S; Bulitta JB; Landersdorfer C; Forrest A; Li J; Nation RL; Tsuji BT
    Pharmacotherapy; 2015 Jan; 35(1):34-42. PubMed ID: 25630411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro Pharmacodynamics and PK/PD in Animals.
    Lee W; Cai Y; Lim TP; Teo J; Chua SC; Kwa AL
    Adv Exp Med Biol; 2019; 1145():105-116. PubMed ID: 31364074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real-world, retrospective cohort study.
    Yang QJ; Xiang BX; Song MH; Yang CY; Liang JH; Xie YL; Zuo XC
    Pharmacotherapy; 2024 Aug; 44(8):631-641. PubMed ID: 39046197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.
    Lin YW; Zhou QT; Han ML; Onufrak NJ; Chen K; Wang J; Forrest A; Chan HK; Li J
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of infections caused by Gram-negative pathogens: current status on the pharmacokinetics/pharmacodynamics of parenteral and inhaled polymyxins in patients.
    Lin YW; Aye SM; Rao G; Zhou QT; Chan HK; Li J
    Int J Antimicrob Agents; 2020 Dec; 56(6):106199. PubMed ID: 33075510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.